{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.3973","pValueComment":"Analysis of covariance (ANCOVA) included treatment group, randomization stratification factors and baseline value of Global Health Status scale.","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.24","value":"-13.5"},{"groupId":"OG001","spread":"24.81","value":"-12.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"202"}],"units":"Participants"}],"description":"EORTC QLQ-C30 v3.0 is a 30-item, self-administered questionnaire with multidimensional scales assessing 15 domains (5 functional domains \\[physical, role, cognitive, emotional, and social\\], 9 symptom scales \\[fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties\\] and global health status scale). 28 questions assessed on a 1 (not at all) to 4 (very much) scale and the remaining 2 questions used a 1 (poor) to 7 (excellent) scale. A linear transformation was applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For the functional domains and global health status scale, higher scores represent a better level of functioning. For symptoms scales, higher scores represented a greater degree of symptoms.","dispersionType":"Standard Deviation","groups":[{"description":"8 mg/kg of ramucirumab (IMC-1121B) was administered by IV infusion on Days 1 and 15 in combination with 80 mg/m² paclitaxel administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle.","id":"OG000","title":"Ramucirumab (IMC-1211B) Plus Paclitaxel"},{"description":"Placebo was administered by IV infusion on Days 1 and 15, in combination with 80 mg/m² paclitaxel administered on Days 1, 8, and 15 of a 28-day cycle.","id":"OG001","title":"Placebo Plus Paclitaxel"}],"paramType":"MEAN","populationDescription":"All participants according to the treatment group to which they were randomized with baseline and end of treatment Global Health Status observations.","reportingStatus":"POSTED","timeFrame":"Baseline, end of therapy (up to 103 weeks)","title":"Change From Baseline to End of Therapy in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life: Questionnaire (QLQ-C30) in Global Health Status","type":"SECONDARY","unitOfMeasure":"units on a scale"}